Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an urgent need to develop therapies to reduce rates of HCV infection of transplanted livers. Approved therapeutics for HCV are poorly tolerated and are of limited efficacy in this patient population. Human mon...
Main Authors: | Trevor J Morin, Teresa J Broering, Brett A Leav, Barbra M Blair, Kirk J Rowley, Elisabeth N Boucher, Yang Wang, Peter S Cheslock, Michael Knauber, David B Olsen, Steve W Ludmerer, Gyongyi Szabo, Robert W Finberg, Robert H Purcell, Robert E Lanford, Donna M Ambrosino, Deborah C Molrine, Gregory J Babcock |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS Pathogens |
Online Access: | http://europepmc.org/articles/PMC3431327?pdf=render |
Similar Items
-
High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.
by: Gregory J Babcock, et al.
Published: (2014-01-01) -
HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01) -
HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis
by: Regina Medvedev, et al.
Published: (2016-01-01) -
Predicting Incidences of HCV and Advanced-Stage HCV Outcomes from the Opioid Epidemic
by: Eisner, Christopher W.
Published: (2020) -
Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
by: Jordan J. Feld, et al.
Published: (2021-06-01)